Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

106.13 +1.57 (+1.50%)
Official Closing Price Updated: 4:10 PM EST, Nov 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S ADR

< Previous 1 2
...
27 28 29 30 31 32 33 34 35
...
65 66 Next >
Amgen Is Trying To Take On Lilly, Novo In Obesity Treatment — Here's Why Lilly Stock Just Hit A Record
Amgen is looking to rival Eli Lilly and Novo Nordisk in weight-loss drugs. 
Via Investor's Business Daily
What's Going On With Eli Lilly Stock Today?
Eli Lilly's stock surge, driven by the upcoming Q4 2023 results and the impact of FDA-approved weight-loss drug Zepbound. 
Via Benzinga
Catalent (CTLT) Stock Pops 10% on Sale to Novo Nordisk
Catalent stock is rising higher on Monday after the company announced a $16.5 billion cash acquisition deal for CTLT shares. 
Via InvestorPlace
Novo Nordisk To Up Production Capacity As Parent Buys Catalent
NVO stock rose after Novo Nordisk's parent, Novo Holdings, said it has agreed to buy contract manufacturer Catalent for $11.5 billion in cash. 
Via Investor's Business Daily
Ozempic Maker Strikes $11B Deal With Catalent As It Rushes To Meet Massive Weight-Loss Drug Demand
This move comes on the heels of the company's recent collaborations to develop new treatment approaches for obesity management and chronic liver diseases. 
Via Benzinga
Deep Dive Into Novo Nordisk Stock: Analyst Perspectives (4 Ratings)
Via Benzinga
Market Whales and Their Recent Bets on NVO Options
Via Benzinga
Earnings Preview: Novo Nordisk
Via Benzinga
Novo Nordisk Options Trading: A Deep Dive into Market Sentiment
Via Benzinga
Is Novo Nordisk a Hot Stock to Buy Now After its Spectacular Q4?
Demand for the company's leading drugs is sky-high, but a giant rival is lying in wait to snatch market share. 
Via The Motley Fool
After a 90% Gain, Is It Too Late to Buy Eli Lilly?
Its drug tirzepatide showed top efficacy as a weight-loss treatment according to the latest real-world data. 
Via The Motley Fool
Stock Market Handles Huge Earnings Week, Fed's Powell, Jobs Report: Weekly Review
The Dow led the major indexes higher. Big techs diverged on results. 
Via Investor's Business Daily
Topics Economy Stocks
Exposures Interest Rates US Equities
Novo Nordisk Stock Just Earned A 92 RS Rating; Gapped Up On Earnings
Novo Nordisk ADR sees its Relative Strength Rating move into the elite 90-plus level. 
Via Investor's Business Daily
The Road to a Trillion: 3 Stocks Next in Line for the Mega Milestone
Becoming a trillion-dollar milestone stock is more than just having a title. Rather, it indicates market dominance in the industry. 
Via InvestorPlace
Why Eli Lilly Stock Topped the Market Today
One of its more recently approved drugs will be launched into a white-hot market. 
Via The Motley Fool
Novo Nordisk (NVO) Q4 2023 Earnings Call Transcript
NVO earnings call for the period ending December 31, 2023. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Novo Nordisk's Wegovy Comes In Light, But Ozempic Puts Up A Commanding Beat
Novo Nordisk stock rose early Wednesday on its fourth-quarter earnings and sales beat. 
Via Investor's Business Daily
Take Your Ozempic: Why Late Entry Of Rival Weight-Loss Drugs Won't Floor Novo, Eli Shares
Eli Lilly to report strong Q4 earnings thanks to successful diabetes treatments, while rivals like Novo Nordisk and Pfizer are also vying for a share of the weight-loss market. 
Via Benzinga
With Bumper $33B Sales, Novo Nordisk Forecasts Double-Digit 2024 Earnings Growth, Boosts Lower Dose Wegovy US Supplies
Novo Nordisk reports impressive Q4 2023 sales of DKK 65.86 billion, up 43% at CER. Explore robust growth in Diabetes and Obesity care, including GLP-1 diabetes and Wegovy. CEO anticipates continued... 
Via Benzinga
Novo Nordisk Skyrockets To $506B Valuation Driven By 'Miracle' Drugs Ozempic, Wegovy
The company predicts a sales growth of 18% to 26% in CER terms for the current year, driven by the soaring demand for Wegovy and Ozempic, which contain the same active ingredient. 
Via Benzinga
Will Novo Nordisk Be a $1 Trillion Company by 2030?
Novo Nordisk's market cap has ballooned thanks to the overwhelming success of its Ozempic, Wegovy, and Rybelsus medications. 
Via The Motley Fool
Eli Lilly Wants to Expand Access to Weight-Loss Treatments In Germany, In Talks With Government
Eli Lilly in talks with German government to lift ban on health system coverage for weight-loss treatments. Explore Mounjaro's recent EU approval and market launches. 
Via Benzinga
Forget The Magnificent Seven. Focus On These Fab Five.
Investors put a lot of attention on Nvidia and the rest of the Magnificent Seven. But two of these S&P 500 giants aren't fabulous. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Earnings Scheduled For January 31, 2024
Companies Reporting Before The Bell • Novartis (NYSE:NVS) is likely to report quarterly earnings at $1.68 per share on revenue of $11.56 billion. 
Via Benzinga
If You Invested $5,000 in Novo Nordisk in 2019, This Is How Much You Would Have Today
The answer may surprise you. 
Via The Motley Fool
Could Eli Lilly Be a Trillion-Dollar Company by 2030?
Eli Lilly is the world's largest healthcare company by market cap, and the 10th most valuable business in the world. 
Via The Motley Fool
Eli Lilly's Famed Obesity And Diabetes Drug, Mounjaro, Comes To UK Patients, Wins Regulatory Clearance For Prefilled Injection Pen
Eli Lilly's MHRA-approved Mounjaro KwikPen offers effective diabetes and weight management. Learn about the four-dose version's benefits for type 2 diabetes patients. 
Via Benzinga
5 Mega-Cap Stocks Ready to Make the Magnificent 7 a Dynamic Dozen
With mega-cap stocks setting new highs, here are five new names that could take the Magnificent 7 to a Dynamic Dozen. 
Via InvestorPlace
5 top healthcare stocks for earnings growth in 2024
2024 holds promise for healthcare stocks, with Humana, Elevance, and others expected to boost earnings, as analysts say many industry pressures have been removed. 
Via MarketBeat
Weight Loss Drug's Ozempic Counterfeit: Rising Reports Over Patient Safety Related Fake Drugs
Discover the alarming rise in fake Ozempic cases, leading to hypoglycemia. Learn about FDA investigations, counterfeit warnings, and the surge in reports. 
Via Benzinga
Exposures Product Safety
< Previous 1 2
...
27 28 29 30 31 32 33 34 35
...
65 66 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.